[go: up one dir, main page]

WO2012016147A2 - Ligands for selective asymmetric hydroformylation - Google Patents

Ligands for selective asymmetric hydroformylation Download PDF

Info

Publication number
WO2012016147A2
WO2012016147A2 PCT/US2011/045897 US2011045897W WO2012016147A2 WO 2012016147 A2 WO2012016147 A2 WO 2012016147A2 US 2011045897 W US2011045897 W US 2011045897W WO 2012016147 A2 WO2012016147 A2 WO 2012016147A2
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
crc
amino
hydroxyl
amido
Prior art date
Application number
PCT/US2011/045897
Other languages
French (fr)
Other versions
WO2012016147A3 (en
Inventor
Christopher James Cobley
Gary Noonan
Matthew Clarke
Original Assignee
Dr. Reddy's Laboratories Ltd.
Dr. Reddy's Laboratories, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr. Reddy's Laboratories Ltd., Dr. Reddy's Laboratories, Inc. filed Critical Dr. Reddy's Laboratories Ltd.
Priority to EP11813250.5A priority Critical patent/EP2598510A4/en
Priority to JP2013522001A priority patent/JP2013532691A/en
Publication of WO2012016147A2 publication Critical patent/WO2012016147A2/en
Publication of WO2012016147A3 publication Critical patent/WO2012016147A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/49Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reaction with carbon monoxide
    • C07C45/50Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reaction with carbon monoxide by oxo-reactions
    • C07C45/505Asymmetric hydroformylation
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/18Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes containing nitrogen, phosphorus, arsenic or antimony as complexing atoms, e.g. in pyridine ligands, or in resonance therewith, e.g. in isocyanide ligands C=N-R or as complexed central atoms
    • B01J31/1845Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes containing nitrogen, phosphorus, arsenic or antimony as complexing atoms, e.g. in pyridine ligands, or in resonance therewith, e.g. in isocyanide ligands C=N-R or as complexed central atoms the ligands containing phosphorus
    • B01J31/185Phosphites ((RO)3P), their isomeric phosphonates (R(RO)2P=O) and RO-substitution derivatives thereof
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/24Phosphines, i.e. phosphorus bonded to only carbon atoms, or to both carbon and hydrogen atoms, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, phosphole or anionic phospholide ligands
    • B01J31/2495Ligands comprising a phosphine-P atom and one or more further complexing phosphorus atoms covered by groups B01J31/1845 - B01J31/1885, e.g. phosphine/phosphinate or phospholyl/phosphonate ligands
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00Preparation of carboxylic acid amides
    • C07C231/12Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C253/00Preparation of carboxylic acid nitriles
    • C07C253/30Preparation of carboxylic acid nitriles by reactions not involving the formation of cyano groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00Preparation of carboxylic acid esters
    • C07C67/28Preparation of carboxylic acid esters by modifying the hydroxylic moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/293Preparation of carboxylic acid esters by modifying the hydroxylic moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6568Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus atoms as the only ring hetero atoms
    • C07F9/65683Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus atoms as the only ring hetero atoms the ring phosphorus atom being part of a phosphine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2231/00Catalytic reactions performed with catalysts classified in B01J31/00
    • B01J2231/30Addition reactions at carbon centres, i.e. to either C-C or C-X multiple bonds
    • B01J2231/32Addition reactions to C=C or C-C triple bonds
    • B01J2231/321Hydroformylation, metalformylation, carbonylation or hydroaminomethylation
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/02Compositional aspects of complexes used, e.g. polynuclearity
    • B01J2531/0261Complexes comprising ligands with non-tetrahedral chirality
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/80Complexes comprising metals of Group VIII as the central metal
    • B01J2531/82Metals of the platinum group
    • B01J2531/822Rhodium
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers

Definitions

  • the invention relates to phosphine-phosphite ligands with a chiral phospholane (S,S)-diphenylphospholane and chiral or achiral biaryl phenols linked by a hydroxym ethyl bridge.
  • the invention provides compounds of the formula 4:
  • Olefin hydroformylation has been practiced industrially for decades for the production of commodity aldehyde intermediates. Since linear regioisomers are desired often, a major industrial focus has been the development of highly linear- selective ligands for rhodium-catalyzed hydroformylation. Several phosphorous- based ligands have been developed which exhibit sufficiently high regioselectivity for linear aldehydes for this methodology to be industrially applicable. Linear regioisomers are desired most often in the commodity chemicals sector. However, in organic synthesis of the more complex molecules used in the fine chemicals and pharmaceutical sector, there are demands for both linear and branched aldehyde regioisomers.
  • the branched regioisomers of the aldehydes are also frequently preferred in optically active form; thus such products can be prepared by regioselective and enantioselective hydroformylation of olefins.
  • the current state-of-the-art catalysts for enantioselective hydroformylation only deliver the branched aldehyde regioisomer for a select number of carefully chosen olefinic substrates.
  • Ph-BPE has shown high activity and enantioselectivity for the asymmetric hydroformylation of selected olefins.
  • Kelliphite a bisphosphite ligand was discovered to be effective for enantioselective hydroformylation after a comprehensive screen of novel ligands of this class.
  • Binaphos an atropisomeric biaryl-based phosphine-phosphite has proven to be a prominent ligand for enantioselective hydroformylation with arguably the widest applicability demonstrated to date with high enantioselectivies observed with a range of terminal olefins bearing aryl, heteroaryl, alkenyl, heteroatom substituted groups, and a range of internal olefins. High enantioselectivity is a common feature in these reactions, with olefinic substrates chosen for their tendency to preferentially form the desired branched isomer giving regioselectivities of between 75% and in exceptional cases 99%.
  • Rh catalysts derived from phosphine-phosphites give similar regioselectivity in the hydroformylation of olefins to simple achiral ligands such as triphenylphosphine or 1 ,2-bis-(diphenylphosphino)ethane.
  • Phosphine-phosphites have been reported lacking the diphenylphospholane moiety.
  • the invention provides compounds of the formula 4:
  • the invention provides compounds of the formula 4:
  • n and m are each independently an integer from 1 to 3;
  • Ar are both independently C-6-Ci 4 aryl or Ci-Cgheteroaryl, which can be unsubstituted or substituted with one or more of the following groups: CrC 6 alkyl-, halogen, CrCehaloalkyl-, hydroxyl, hydroxyl(CrC 6 alkyl)-, H 2 N-, (C C 6 alkyl)amino-, di(Ci-C 6 alkyl)amino-, HO2C-, (CrC 6 alkoxy)carbonyl-, (d- C 6 alkyl)carboxyl-, di(CrC 6 alkyl)amido-, H 2 NC(0)-, (CrC 6 alkyl)amido-, or 0 2 N-; -Ar ⁇ -Ar 2 - is a bi(C 6 -Ci 4 aryl), bi(Ci-C 9 heteroaryl), or -(C 6 -Ci 4 aryl)-(Ci-
  • the invention provides compound 3b (Fig. 3 crystal structure and Fig.4).
  • Fig. 3 Crystal structure of diphenyl-phospholane-phosphite ligand 3b
  • the invention provides compounds of the formulae 1 , 2a, 2b, and 3b.
  • the invention provides a synthesis of 2-phenylpropanal from styrene and Syn gas in the presence of Rh catalysts derived from ligands of formula 4.
  • the invention provides a synthesis of 3-methyl-4- oxobutanenitrile from allyl cyanide and Syn gas in the presence of Rh catalysts derived from ligands of formula 4.
  • the invention provides a synthesis of 1 -oxopropan-2-yl acetate from vinyl acetate and Syn gas in the presence of Rh catalysts derived from ligands of formula 4.
  • Table 1 are shown the results for the above hydroformylation of styrene using catalysts derived from ligands of type 4, which identified ligand 3b as the most enantioselective ligand.
  • Table 1 Rh catalyzed hydroformylation of styrene
  • Iigand1-3b (0.5%) , 1 mmol styrene, 3.5 ml_ toluene.
  • the invention provides a regioselective synthesis of 2-methyl- 3-phenylpropan-1 -al from allyl benzene and Syngas in the presence of an Rh catalyst derived from ligands of type 4, under conditions where ligands outside the phospholane-phosphite class give no selectivity as shown in Table 2.
  • BH 3 DMS is borane dimethyl sulfide complex ((CH 3 ) 2 S BH 3 ), DABCO is 1 ,4-diazabicyclo[2.2.2]octane, r. t. is room temperature, TMS-I is iodotrimethylsilane.
  • % e. e means the enantiomeric excess of a substance, which is defined as the absolute difference between the mole fraction of each enantiomer.
  • the number of carbon atoms present in a given group is designated "C x -C y ", where x and y are the lower and upper limits, respectively.
  • a group designated as " ⁇ - ⁇ - ⁇ ” contains from 1 to 6 carbon atoms.
  • the carbon number as used in the definitions herein refers to carbon backbone and carbon branching, but does not include carbon atoms of the substituents, such as alkoxy substitutions and the like. Unless indicated otherwise, the nomenclature of substituents that are not explicitly defined herein are arrived at by naming from left to right the terminal portion of the functionality followed by the adjacent functionality toward the point of attachment.
  • arylalkyloxycabonyl refers to the group (C 6 -Ci 4 aryl)-(Ci-C 6 alkyl)-O- C(O)-. It is understood that the above definitions are not intended to include impermissible substitution patterns (e.g., methyl substituted with 5 fluoro groups). Such impermissible substitution patterns are well known to the skilled artisan.
  • the carbon number as used in the definitions herein refers to carbon backbone and carbon branching, but does not include carbon atoms of the substituents, such as alkoxy substitutions and the like.
  • (Alkoxy)carbonyl refers to the group alkyl-O-C(O)-.
  • Exemplary (Cr C 6 alkoxy)carbonyl groups include but are not limited to methoxy, ethoxy, n- propoxy, 1 -propoxy, n-butoxy, and t-butoxy.
  • An (alkoxy)carbonyl group can be unsubstituted or substituted with one or more of the following groups: halogen, hydroxyl, -NH 2 , (C C 6 alkyl)N-, (Ci-C 6 alkyl)(Ci-C 6 alkyl)N-, -N(C C 3 alkyl)C(0)(Ci- Cealkyl), -NHC(0)(Ci-C 6 alkyl), -NHC(0)H, -C(0)NH 2 , -C(0)NH(CrC 6 alkyl), - C(0)N(Ci-C 6 alkyl)(Ci-C 6 alkyl), -CN, C C 6 alkoxy, -C(0)OH, -C(0)0(C C 6 alkyl), - C(O)(d-C 6 alkyl), C 6 -C 14 aryl, C C 9 heteroaryl, C 3 -C 8 cycloalkyl, Ci-C 6 haloalkyl
  • Alkyl- refers to a hydrocarbon chain that may be a straight chain or branched chain, containing the indicated number of carbon atoms, for example, a C-
  • C C 6 alkyl- groups include, but are not limited to, methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, isobutyl, sec-butyl, tert-butyl, isopentyl, neopentyl, and isohexyl.
  • An alkyl- group can be unsubstituted or substituted with one or more of the following groups: halogen, H 2 N-, (Ci-C 6 alkyl)amino-, di(Ci-C 6 alkyl)amino-, (C C- 6 alkyl)C(0)N(Cr C 3 alkyl)-, (C C 6 alkyl)carboxyamido-, HC(0)NH-, H 2 NC(O)-, (Ci-C 6 alkyl)NHC(0)-, di(Ci-C 6 alkyl)NC(O)-, NC-, hydroxyl, CrC 6 alkoxy-, CrC 6 alkyl-, HO 2 C-, (C C 6 alkoxy)carbonyl-, (CrC 6 alkyl)C(0)-, C 6 -C aryl-, C-i-Cgheteroaryl-, C 3 - Cscycloalkyl-, CrC 6 haloalkyl-, amino
  • (Alkyl)amido- refers to a -C(0)NH- group in which the nitrogen atom of said group is attached to an alkyl group, as defined above.
  • Representative examples of a (CrC 6 alkyl)amido group include, but are not limited to, - C(O)NHCH 3 , -C(0)NHCH 2 CH 3 , -C(0)NHCH 2 CH 2 CH 3 , -C(0)NHCH 2 CH 2 CH 2 CH 3l - C(0)NHCH 2 CH 2 CH 2 CH 2 CH 3 , -C(O)NHCH(CH 3 ) 2 , -C(0)NHCH 2 CH(CH 3 ) 2l - C(0)NHCH(CH 3 )CH 2 CH 3 , -C(O)NH-C(CH 3 ) 3 and -C(0)NHCH 2 C(CH 3 ) 3 .
  • (Alkyl)amino- refers to an -NH group, the nitrogen atom of said group being attached to an alkyl group, as defined above.
  • Representative examples of an (Ci-C 6 alkyl)amino- group include, but are not limited to CH 3 NH-, CH 3 CH 2 NH-, CH 3 CH 2 CH 2 NH-, CH 3 CH 2 CH 2 CH 2 NH-, (CH 3 ) 2 CHNH-, (CH 3 ) 2 CHCH 2 NH-, CH 3 CH 2 CH(CH 3 )NH- and (CH 3 ) 3 CNH-.
  • An (alkyl)amino group can be unsubstituted or substituted with one or more of the following groups: halogen, ⁇ 2 ⁇ -, (CrC 6 alkyl)amino-, di(CrC 6 alkyl)amino-, (Ci-C 6 alkyl)C(0)N(CrC 3 alkyl)-, (CrC 6 alkyl)carboxyamido-, HC(0)NH-, H 2 NC(0)-, (d-C 6 alkyl)NHC(0)-, di(C C 6 alkyl)NC(0)-, NC-, hydroxyl, C C 6 alkoxy-, C C 6 alkyl-, H0 2 C-, (C C 6 alkoxy)carbonyl-, (CrC 6 alkyl)C(0)-, C 6 -Ci 4 aryl-, Ci-Cgheteroaryl-, C 3 - Cscycloalkyl-, CrC 6 haloalkyl-, amino(
  • Alkylcarboxy refers to an alkyl group, defined above, attached to the parent structure through the oxygen atom of a carboxyl (C(O)-O-) functionality.
  • Examples of (CrC 6 alkyl)carboxy include acetoxy, ethylcarboxy, propylcarboxy, and isopentylcarboxy.
  • Aryl- refers to an aromatic hydrocarbon group.
  • Examples of an C 6 - Ci 4 aryl- group include, but are not limited to, phenyl, 1 -naphthyl, 2-naphthyl, 3- biphen-1 -yl, anthryl, tetrahydronaphthyl, fluorenyl, indanyl, biphenylenyl, and acenaphthenyl.
  • An aryl group can be unsubstituted or substituted with one or more of the following groups: CrC 6 alkyl-, halogen, haloalkyl-, hydroxyl, hydroxyl(CrC 6 alkyl)-, H 2 N-, amino(C C 6 alkyl)-, di(CrC 6 alkyl)amino-, H0 2 C-, (Ci- C 6 alkoxy)carbonyl-, (C C 6 alkyl)carboxyl-, di(Ci-C 6 alkyl)amido-, H 2 NC(0)-, (C C 6 alkyl)amido-, or 0 2 N-.
  • Di(alkyl)amido- refers to a -NC(O)- group in which the nitrogen atom of said group is attached to two alkyl groups, as defined above. Each alkyl group can be independently selected.
  • Representative examples of a di(C C 6 alkyl)amido- group include, but are not limited to, -C(O)N(CH 3 ) 2 , - C(O)N(CH 2 CH 3 ) 2 , -C(O)N(CH 3 )CH 2 CH 3) -C(0)N(CH 2 CH 2 CH 2 CH 3 ) 2 , -C(0)N(CH 2 CH 3 )CH 2 CH 2 CH 3 , -C(0)N(CH 3 )CH(CH 3 ) 2l -C(O)N(CH 2 CH 3 )CH 2 CH(CH 3 ) 2 , - C(0)N(CH(CH 3 )CH 2 CH 3 ) 2> -C(O)N(CH 2 CH 3 )C(CH 3
  • Di(alkyl)amino- refers to a nitrogen atom attached to two alkyl groups, as defined above. Each alkyl group can be independently selected.
  • Representative examples of an di(CrC 6 alkyl)amino- group include, but are not limited to, - N(CH 3 ) 2 , -N(CH 2 CH 3 )(CH 3 ), -N(CH 2 CH 3 ) 2 , -N(CH 2 CH 2 CH 3 ) 2 , N(CH 2 CH 2 CH 2 CH 3 ) 2 , -N(CH(CH 3 ) 2 ) 2 , -N(CH(CH 3 ) 2 )(CH 3 ), -N(CH 2 CH(CH 3 ) 2 ) 2 , - NH(CH(CH 3 )CH 2 CH 3 ) 2 , -N(C(CH 3 ) 3 ) 2, -N(C(CH 3 ) 3 )(CH 3 ), and -N(CH 3 )(CH 2
  • the two alkyl groups on the nitrogen atom when taken together with the nitrogen to which they are attached, can form a 3- to 7- membered nitrogen containing heterocycle wherein up to two of the carbon atoms of the heterocycle can be replaced with -N(H)-, -N(CrC 6 alkyl)-, -N(C 3 -C 8 cycloalkyl)-, -N(C 6 -C 4 aryl)-, -N(d- Cgheteroaryl)-, -N(amino(Ci-C 6 alkyl))-, -N(C 6 -Ci 4 arylamino)-, -O-, -S-, -S(O)-, or - S(0) 2 -.
  • Halo or halogen refers to fluorine, chlorine, bromine, or iodine.
  • Haloalkyl- refers to an alkyl group, as defined above, wherein one or more of the Ci-C 6 alkyl group's hydrogen atoms has been replaced with -F, -CI, - Br, or -I. Each substitution can be independently selected from -F, -CI, -Br, or -I.
  • Ci-C 6 haloalkyl- group include, but are not limited to, -CH 2 F, -CCI 3 , -CF 3 , CH 2 CF 3 , -CH 2 CI, -CH 2 CH 2 Br, -CH 2 CH 2 I, -CH 2 CH 2 CH 2 F, - CH 2 CH 2 CH 2 CI, -CH 2 CH 2 CH 2 CH 2 Br, -CH 2 CH 2 CH 2 CH 2 I, -CH CH 2 CH 2 CH 2 CH 2 Br, - CH 2 CH 2 CH 2 CH 2 CH 2 I, -CH 2 CH(Br)CH 3 , -CH 2 CH(CI)CH 2 CH 3 , -CH(F)CH 2 CH 3 and - C(CH 3 ) 2 (CH 2 CI).
  • Heteroaryl- refers to 5-10-membered mono and bicyclic aromatic groups containing at least one heteroatom selected from oxygen, sulfur, and nitrogen.
  • monocyclic Ci -Cgheteroaryl- radicals include, but are not limited to, oxazinyl, thiazinyl, diazinyl, triazinyl, thiadiazoyi, tetrazinyl, imidazolyl, tetrazolyl, isoxazolyl, furanyl, furazanyl, oxazolyl, thiazolyl, thiophenyl, pyrazolyl, triazolyl, pyrimidinyl, N-pyridyl, 2-pyridyl, 3-pyridyl, and 4-pyridyl.
  • bicyclic C Cgheteroaryl- radicals include but are not limited to, benzimidazolyl, indolyl, isoquinolinyl, benzofuranyl, benzothiophenyl, indazolyl, quinolinyl, quinazolinyl, purinyl, benzisoxazolyl, benzoxazolyl, benzthiazolyl, benzodiazolyl, benzotriazolyl, isoindolyl, and indazolyl.
  • the contemplated heteroaryl- rings or ring systems have a minimum of 5 members.
  • Ci heteroaryl- radicals would include but are not limited to tetrazolyl
  • C 2 heteroaryl- radicals include but are not limited to triazolyl, thiadiazoyi, and tetrazinyl
  • Cgheteroaryl- radicals include but are not limited to quinolinyl and isoquinolinyl.
  • a heteroaryl group can be unsubstituted or substituted with one or more of the following groups: C-i-C 6 alkyl-, halogen, CrC 6 haloalkyl-, hydroxyl, Ci-C 6 hydroxylalkyl-, H 2 N-, amino(Ci-C 6 alkyl), di(Ci-C 6 alkyl)amino-, -COOH, (CrC 6 alkoxy)carbonyl-, (CrC 6 alkyl)carboxyl-, di(CrC 6 alkyl)ainnido-, H 2 NC(0)-, (Ci-C 6 alkyl)amido-, or 0 2 N-.
  • “Hydroxylalkyl-” refers to an alkyl group, as defined above, wherein one or more of the C-i-Cealkyl group's hydrogen atoms have been replaced with hydroxyl groups.
  • Examples of hydroxyl (C Cealkyl)- moieties include, for example, - CH 2 OH, -CH 2 CH 2 OH, -CH 2 CH 2 CH 2 OH, -CH 2 CH(OH)CH 2 OH, -CH 2 CH(OH)CH 3 , - CH(CH 3 )CH 2 OH and higher homologs.
  • leaving group refers to an atom or group (charged or uncharged) that becomes detached from an atom in what is considered to be the residual or main part of the substrate in a specified reaction.
  • the leaving group is bromide.
  • the leaving group is trimethylamine.
  • the electrophilic nitration of benzene it is H + .
  • the term has meaning only in relation to a specified reaction. Examples of leaving groups include, for example, carboxylates ⁇ i.e.
  • EXAMPLE 6 Regioselective and enantioselective hydroformylation of Vinyl acetate. This reaction was run in an Argonaut Endeavour parallel autoclave system (AE). The vessels of the AE were flushed with Syngas. Stock solutions of [Rh(acac)(CO) 2 ] and ligand 3a were prepared as 1 mg per ml_ solution in toluene. 1 ml of the rhodium stock solution, (1 mg, 0.004 mmol, 0.4 mol%) and a stock solution equivalent to 0.005 mmol (0.5%) of ligand 3a were added into a well in the AE. The mixture was pressurized to 5 bar Syngas and heated at 50 °C for 40 minutes.
  • the pressure was then vented and the apparatus cooled to room temperature.
  • the require substrate (vinyl acetate 1 mmol) was then added also as a stock solution in toluene to bring the reaction vessel up to 3.5 ml_ volume.
  • the apparatus was then purged three times with Syngas, placed at 2.5 bar pressure and heated to 60 °C at constant pressure for 4 hours, after which time no further Syngas uptake was used up (>99% conversion).
  • the AE was then cooled and the reaction mixture analyzed by GC in the standard protocol using a beta- Dex 225 chiral column. This along with NMR revealed that the only product present was the branched aldehyde (B / L >99:1 ) and with an e. e.. of 83 %.
  • EXAMPLE 7 Regioselective and enantioselective hydroformylation of styrene. This reaction was run in an Argonaut Endeavour parallel autoclave system (AE). The vessels of the AE were flushed with Syngas. Stock solutions of [Rh(acac)(CO) 2 ] and ligand 3a were prepared as 1 mg per mL solution in toluene. 1 ml of the rhodium stock solution, (1 mg, 0.004 mmol, 0.4 mol%) and a stock solution equivalent to 0.005 mmol (0.5%) of ligand 3a were added into a well in the AE. The mixture was pressurized to 5 bar Syngas and heated at 50 °C for 40 minutes.
  • the pressure was then vented and the apparatus cooled to room temperature.
  • the require substrate (styrene 1 mmol) was then added also as a stock solution in toluene to bring the reaction vessel up to 3.5 mL volume.
  • the apparatus was then purged three times with Syngas, placed at 10 bar pressure and heated to 60 °C at constant pressure for 6 hours, after which time no further Syngas uptake was used up (>99% conversion).
  • EXAMPLE 8 Regioselective and enantioselective hydroformylation of allyl cyanide. This reaction was run in an Argonaut Endeavour parallel autoclave system (AE). The vessels of the AE were flushed with Syngas. Stock solutions of [Rh(acac)(CO)2] and ligand 3a were prepared as 1 mg per ml_ solution in toluene. 1 ml of the rhodium stock solution, (1 mg, 0.004 mmol, 0.4 mol%) and a stock solution equivalent to 0.005 mmol (0.5%) of ligand 3a were added into a well in the AE. The mixture was pressurized to 5 bar Syngas and heated at 50 °C for 40 minutes.
  • the pressure was then vented and the apparatus cooled to room temperature.
  • the require substrate (allyl cyanide, 1 mmol) was then added also as a stock solution in toluene to bring the reaction vessel up to 3.5 mL volume.
  • the apparatus was then purged three times with Syngas, placed at 10 bar pressure and heated to 30 °C at constant pressure for 14 hours, after which time no further Syngas uptake was used up (>99% conversion).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

In an aspect, the invention provides compounds of the formula 4: wherein the constituent variables are defined herein.

Description

LIGANDS FOR SELECTIVE ASYMMETRIC HYDROFORMYLATION
INTRODUCTION
The invention relates to phosphine-phosphite ligands with a chiral phospholane (S,S)-diphenylphospholane and chiral or achiral biaryl phenols linked by a hydroxym ethyl bridge. In one aspect, the invention provides compounds of the formula 4:
Figure imgf000002_0001
4
wherein the constituent variables are defined below.
Olefin hydroformylation has been practiced industrially for decades for the production of commodity aldehyde intermediates. Since linear regioisomers are desired often, a major industrial focus has been the development of highly linear- selective ligands for rhodium-catalyzed hydroformylation. Several phosphorous- based ligands have been developed which exhibit sufficiently high regioselectivity for linear aldehydes for this methodology to be industrially applicable. Linear regioisomers are desired most often in the commodity chemicals sector. However, in organic synthesis of the more complex molecules used in the fine chemicals and pharmaceutical sector, there are demands for both linear and branched aldehyde regioisomers. In the latter case, the branched regioisomers of the aldehydes are also frequently preferred in optically active form; thus such products can be prepared by regioselective and enantioselective hydroformylation of olefins. The current state-of-the-art catalysts for enantioselective hydroformylation only deliver the branched aldehyde regioisomer for a select number of carefully chosen olefinic substrates. In the case of terminal olefins, these take the form R-CH=CH2 where Ar = aryl, heteroaryl or heteroatom, and XCH2CH=CH2 where X = heteroatom or CN. These catalysts deliver very poor regioselectivity in favor of the branched aldehydes for the hydroformylation of alkenes of type RCH2CH=CH2, where R refers to an aryl, heteroaryl or alkyl group or functionalized derivative as defined herein. In addition, There is also an unmet need to attain extremely high regioselectivity (>99%) in the cases of olefins where the state of the art catalysts only provide moderate regioselectivity for the branched isomer. The invention described here addressed these unmet needs.
Significant advances in chiral ligand design have been made recently which have led to increased enantioselectivity in hydroformylation. Three such advances are Ph-BPE [Klosin et al, Angew. Chem. Int. Ed. 2005, 44, 5834], Kelliphite [Whiteker et al, J. Org. Chem., 2004, 6, 3277], and Binaphos [Takaya et al, J. Am. Chem. Soc, 1997, 1 19, 4413]. The structures of these three ligands are shown below in Figure 1 .
Figure imgf000003_0001
CR,S)-BINAPHOS Figure 1
Ph-BPE has shown high activity and enantioselectivity for the asymmetric hydroformylation of selected olefins. Kelliphite, a bisphosphite ligand was discovered to be effective for enantioselective hydroformylation after a comprehensive screen of novel ligands of this class. Binaphos, an atropisomeric biaryl-based phosphine-phosphite has proven to be a prominent ligand for enantioselective hydroformylation with arguably the widest applicability demonstrated to date with high enantioselectivies observed with a range of terminal olefins bearing aryl, heteroaryl, alkenyl, heteroatom substituted groups, and a range of internal olefins. High enantioselectivity is a common feature in these reactions, with olefinic substrates chosen for their tendency to preferentially form the desired branched isomer giving regioselectivities of between 75% and in exceptional cases 99%. However, it has also been demonstrated that, in common with other types of hydroformylation catalyst, hydroformylation of an olefin of type RCH2CH=CH2 does not deliver the branched aldehyde selectively; in fact only around 25% of the aldehydes formed from a typical substrate, hex-1 -ene are the desired branched regioisomer as demonstrated in "Asymmetric hydroformylation catalyzed by an Rh(l)-(R,S)-BINAPHOS complex: substituent effects on the regioselectivity", J. Organomet. Chem. 1997, 527, 103. Research described in "Substituent Effect in Asymmetric Hydroformylation of Olefins Catalysed by Rhodium(l) Complexes of (fi,Sj-BINAPHOS Derivatives: A protocol for improvement of regio- and enantio-selectivities", Adv. Synth. Catal. 2001 , 343, 61 ; seeks to improve this situation, but only results in a poor 29.8% selectivity for enantioselective hydroformylation of hex-1 -ene. It is therefore widely known that Rh catalysts derived from phosphine-phosphites, up to now, give similar regioselectivity in the hydroformylation of olefins to simple achiral ligands such as triphenylphosphine or 1 ,2-bis-(diphenylphosphino)ethane. Despite many catalysts having been investigated for this transformation, this problem remained unsolved and is reflected in quotes from two authorative reviews; "the preferred formation of the branched aldehyde in particular for simple alkyl substituted alkenes is an unsolved problem" quoted from "Recent Advances in Chemo-, Regio- and Stereoselective Hydroformylation", Synthesis, 2001 , 1 , and similar conclusions in "Branched Selective Hydroformylation", Curr. Org. Chem. 2005, 9, 701 . There is a strong industrial demand for such branched aldehydes or products obtained directly from them as evidenced by less direct protocols described by "Hydrogenation Processes in the Synthesis of Perfumery Ingredients", Acc. Chem. Res. 2007, 40, 1312 and " The Synthesis of the High Potency Sweetener NC- 00637 Part 1 : The Synthesis of (S)-2-Methyl Hexanoic Acid", Org. Proc. Res. Dev. 2003, 7, 369.
Phosphine-phosphites have been reported lacking the diphenylphospholane moiety. The closest example is from Landis using a 1 ,2- benzene backbone and the diazaphospholane moiety for the phosphine, the best result for these ligands is 90% e. e. with b/l = 20 for styrene as referred to in "Highly Enantioselective Hydroformylation of Aryl Alkenes with Diazaphospholane Ligands", Organic Letters, 2008), 10(20), 4553;. Further examples of phosphine- phosphites that do not contain a phospholane moiety include "Asymmetric Hydroformylation Using Taddol-Based Chiral Phosphine-Phosphite Ligands", Organometallics 2010, 29(2), 478; "Asymmetric Hydroformylation of Olefins with Rh Catalysts Modified with Chiral Phosphine-Phosphite Ligands", Organometallics 2007, 26(25), 6428; "Synthesis of a chiral phosphite-phosphine ligand, its coordination behavior with rhodium(l) cation and the application in catalytic reaction", Zhongshan Daxue Xuebao, Ziran Kexueban, 2006, 45(4), 58; "Tuning of the structures of chiral phosphane-phosphites: application to the highly enantioselective synthesis of a-acyloxy phosphonates by catalytic hydrogenation", Chemistry-A European Journal 2007, 13(6), 1821 .
The research described in "Rhodium(l), Palladium(ll), and Platinum(ll) Complexes Containing New Mixed Phosphane-Phoshite Ligands - Effect of the Catalytic System stability on the Enantioselective Hydroformylation of Styrene", Eur. J. Inorg. Chem., 2002, 71 1 ; shows that chiral phosphine-phosphites containing a CH2O backbone but lacking a phospholane moiety are precedented, but do not give any notable enantioselectivity.
Despite the widespread nature of phosphine-phosphites, it is clear that there are no examples containing phospholane groups (as opposed to diazaphospholane groups) as the phosphine part of the ligand. Secondly, since there are no obvious leads to solve the problem of control of regioselectivity in hydroformylation of olefins of type RCH2CH=CH2, the examination of this distinct ligand class was examined, leading to the invention described herein. The hydroxymethyl bridge was selected as an initial starting backbone due to ease of synthesis. Thus, this family of ligands uses the diphenylphospholane moiety as the phosphine donor and CH20 as the backbone. As a result they are easier to make than those phosphine-phosphites previously reported. More importantly, the results obtained using these ligands show that they have unique performance in producing the branched aldehyde in hydroformylation of olefins of type RCH2CH=CH2, and, in addition provide amongst the highest combination of regioselectivities and enantioselectivities observed in the hydroformylation of other olefin substrates. These ligands offer ease of synthesis, higher enantioselectivities, and higher regioselectivities.
SUMMARY
In one aspect, the invention provides compounds of the formula 4:
Figure imgf000006_0001
4
wherein the constituent variables are defined below.
DETAILED DESCRIPTION In one aspect, the invention provides compounds of the formula 4:
Figure imgf000006_0002
wherein n and m are each independently an integer from 1 to 3;
Ar are both independently C-6-Ci4aryl or Ci-Cgheteroaryl, which can be unsubstituted or substituted with one or more of the following groups: CrC6alkyl-, halogen, CrCehaloalkyl-, hydroxyl, hydroxyl(CrC6alkyl)-, H2N-, (C C6alkyl)amino-, di(Ci-C6alkyl)amino-, HO2C-, (CrC6alkoxy)carbonyl-, (d- C6alkyl)carboxyl-, di(CrC6alkyl)amido-, H2NC(0)-, (CrC6alkyl)amido-, or 02N-; -Ar^-Ar2- is a bi(C6-Ci4aryl), bi(Ci-C9heteroaryl), or -(C6-Ci4aryl)-(Ci- Cgheteroaryl)- diradical, which can be unsubstituted or substituted with one or more of the following groups: CrC6alkyl-, halogen, d-Cehaloalkyl-, hydroxyl, hydroxyl(CrC6alkyl)-, H2N-, (C C6alkyl)amino-, di(C C6alkyl)amino-, H02C-, (C C6alkoxy)carbonyl-, (C C6alkyl)carboxyl-, di(Ci-C6alkyl)amido-, H2NC(0)-, (C C6alkyl)amido-, or O2N-.
In one aspect, the invention provides compound 3b (Fig. 3 crystal structure and Fig.4).
Figure imgf000007_0001
Fig. 3 Crystal structure of diphenyl-phospholane-phosphite ligand 3b In one aspect, the invention provides compounds of the formulae 1 , 2a, 2b, and 3b.
Figure imgf000008_0001
Figure imgf000008_0002
Figure imgf000008_0003
4
In one aspect the invention provides a synthesis of 2-phenylpropanal from styrene and Syn gas in the presence of Rh catalysts derived from ligands of formula 4.
Figure imgf000009_0001
In one aspect the invention provides a synthesis of 3-methyl-4- oxobutanenitrile from allyl cyanide and Syn gas in the presence of Rh catalysts derived from ligands of formula 4.
Figure imgf000009_0002
In one aspect the invention provides a synthesis of 1 -oxopropan-2-yl acetate from vinyl acetate and Syn gas in the presence of Rh catalysts derived from ligands of formula 4.
Figure imgf000009_0003
These results using in-situ formation Rh complexes of 3b are summarized
Figure imgf000009_0004
in Table 1 branched linear
In Table 1 are shown the results for the above hydroformylation of styrene using catalysts derived from ligands of type 4, which identified ligand 3b as the most enantioselective ligand. Table 1 ; Rh catalyzed hydroformylation of styrene
Figure imgf000010_0002
3 T= 30 °C, S:G= 250:1 , Catalyst formed from 0.4 % [Rh(acac)(CO)2]
and Iigand1-3b (0.5%) , 1 mmol styrene, 3.5 ml_ toluene.
b calculated by GC of crude reaction mixture on a Beta Dex 225 chiral column.
c Initial Pressure = 10 bar
In one aspect the invention provides a regioselective synthesis of 2-methyl- 3-phenylpropan-1 -al from allyl benzene and Syngas in the presence of an Rh catalyst derived from ligands of type 4, under conditions where ligands outside the phospholane-phosphite class give no selectivity as shown in Table 2.
Table 2. Hydroformylation of allyl benzene, using a range of hydroformylation cataly
Figure imgf000010_0001
(L)
Figure imgf000010_0003
[a] Catalysts preformed from 0.4 % [Rh(acac)(CO)2] and 0.5 % bidentate ligand
or 1.2% monodentate ligand by stirring at 5 bar Syngas at 50 "C for 40 minutes
in toluene (3 ml), prior to running reactions at room temperature at 5 bar
initial syngas pressure for 3 days. Dppe = l,2-bis-(diphenylphosphino)ethane
[b] % Product determined by Ή NMR using tetraefhylsilane as internal standard.
[c] Determined by HPLC analysis of the alcohol formed after reduction with NaBH4 (Chiracel OD-H) [d] 53 % isolated yield of the corresponding alcohol over 2 steps.
[e] Reaction time of 4 hours at 30 °C. In one aspect the invention provides a method by which the natural regioselectivity of the Rh catalyzed hydroformylation towards linear aldehydes from olefins of type RCH2CH=CH2 as previously defined is reversed towards the branched regioisomer by the use of phospholane-phosphites as ligands for the catalyst.
DEFINITIONS
The following definitions are used in connection with the present invention unless the context indicates otherwise. BH3DMS is borane dimethyl sulfide complex ((CH3)2S BH3), DABCO is 1 ,4-diazabicyclo[2.2.2]octane, r. t. is room temperature, TMS-I is iodotrimethylsilane. The term "% e. e." means the enantiomeric excess of a substance, which is defined as the absolute difference between the mole fraction of each enantiomer.
In general, the number of carbon atoms present in a given group is designated "Cx-Cy", where x and y are the lower and upper limits, respectively. For example, a group designated as "Ο-ι-Οβ" contains from 1 to 6 carbon atoms. The carbon number as used in the definitions herein refers to carbon backbone and carbon branching, but does not include carbon atoms of the substituents, such as alkoxy substitutions and the like. Unless indicated otherwise, the nomenclature of substituents that are not explicitly defined herein are arrived at by naming from left to right the terminal portion of the functionality followed by the adjacent functionality toward the point of attachment. For example, the substituent "arylalkyloxycabonyl" refers to the group (C6-Ci4aryl)-(Ci-C6alkyl)-O- C(O)-. It is understood that the above definitions are not intended to include impermissible substitution patterns (e.g., methyl substituted with 5 fluoro groups). Such impermissible substitution patterns are well known to the skilled artisan. The carbon number as used in the definitions herein refers to carbon backbone and carbon branching, but does not include carbon atoms of the substituents, such as alkoxy substitutions and the like.
"(Alkoxy)carbonyl" refers to the group alkyl-O-C(O)-. Exemplary (Cr C6alkoxy)carbonyl groups include but are not limited to methoxy, ethoxy, n- propoxy, 1 -propoxy, n-butoxy, and t-butoxy. An (alkoxy)carbonyl group can be unsubstituted or substituted with one or more of the following groups: halogen, hydroxyl, -NH2, (C C6alkyl)N-, (Ci-C6alkyl)(Ci-C6alkyl)N-, -N(C C3alkyl)C(0)(Ci- Cealkyl), -NHC(0)(Ci-C6alkyl), -NHC(0)H, -C(0)NH2, -C(0)NH(CrC6alkyl), - C(0)N(Ci-C6alkyl)(Ci-C6alkyl), -CN, C C6alkoxy, -C(0)OH, -C(0)0(C C6alkyl), - C(O)(d-C6alkyl), C6-C14aryl, C C9heteroaryl, C3-C8cycloalkyl, Ci-C6haloalkyl-, C C6aminoalkyl-, -OC(0)(CrC6alkyl), Ci-C6carboxyamidoalkyl-, or -N02.
"Alkyl-" refers to a hydrocarbon chain that may be a straight chain or branched chain, containing the indicated number of carbon atoms, for example, a C-|-Ci0alkyl- group may have from 1 to 10 (inclusive) carbon atoms in it. In the absence of any numerical designation, "alkyl" is a chain (straight or branched) having 1 to 6 (inclusive) carbon atoms in it. Examples of C C6alkyl- groups include, but are not limited to, methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, isobutyl, sec-butyl, tert-butyl, isopentyl, neopentyl, and isohexyl. An alkyl- group can be unsubstituted or substituted with one or more of the following groups: halogen, H2N-, (Ci-C6alkyl)amino-, di(Ci-C6alkyl)amino-, (C C-6alkyl)C(0)N(Cr C3alkyl)-, (C C6alkyl)carboxyamido-, HC(0)NH-, H2NC(O)-, (Ci-C6alkyl)NHC(0)-, di(Ci-C6alkyl)NC(O)-, NC-, hydroxyl, CrC6alkoxy-, CrC6alkyl-, HO2C-, (C C6alkoxy)carbonyl-, (CrC6alkyl)C(0)-, C6-C aryl-, C-i-Cgheteroaryl-, C3- Cscycloalkyl-, CrC6haloalkyl-, amino(Ci-C6alkyl)-, (CrC6alkyl)carboxyl-, C C6carboxyamidoalkyl-, or 02N-.
"(Alkyl)amido-" refers to a -C(0)NH- group in which the nitrogen atom of said group is attached to an alkyl group, as defined above. Representative examples of a (CrC6alkyl)amido group include, but are not limited to, - C(O)NHCH3, -C(0)NHCH2CH3, -C(0)NHCH2CH2CH3, -C(0)NHCH2CH2CH2CH3l - C(0)NHCH2CH2CH2CH2CH3, -C(O)NHCH(CH3)2, -C(0)NHCH2CH(CH3)2l - C(0)NHCH(CH3)CH2CH3, -C(O)NH-C(CH3)3 and -C(0)NHCH2C(CH3)3.
"(Alkyl)amino-" refers to an -NH group, the nitrogen atom of said group being attached to an alkyl group, as defined above. Representative examples of an (Ci-C6alkyl)amino- group include, but are not limited to CH3NH-, CH3CH2NH-, CH3CH2CH2NH-, CH3CH2CH2CH2NH-, (CH3)2CHNH-, (CH3)2CHCH2NH-, CH3CH2CH(CH3)NH- and (CH3)3CNH-. An (alkyl)amino group can be unsubstituted or substituted with one or more of the following groups: halogen, Η2Ν-, (CrC6alkyl)amino-, di(CrC6alkyl)amino-, (Ci-C6alkyl)C(0)N(CrC3alkyl)-, (CrC6alkyl)carboxyamido-, HC(0)NH-, H2NC(0)-, (d-C6alkyl)NHC(0)-, di(C C6alkyl)NC(0)-, NC-, hydroxyl, C C6alkoxy-, C C6alkyl-, H02C-, (C C6alkoxy)carbonyl-, (CrC6alkyl)C(0)-, C6-Ci4aryl-, Ci-Cgheteroaryl-, C3- Cscycloalkyl-, CrC6haloalkyl-, amino(CrC6alkyl)-, (CrC6alkyl)carboxyl-, C C6carboxyamidoalkyl-, or 02N-.
"Alkylcarboxy" refers to an alkyl group, defined above, attached to the parent structure through the oxygen atom of a carboxyl (C(O)-O-) functionality. Examples of (CrC6alkyl)carboxy include acetoxy, ethylcarboxy, propylcarboxy, and isopentylcarboxy.
"Aryl-" refers to an aromatic hydrocarbon group. Examples of an C6- Ci4aryl- group include, but are not limited to, phenyl, 1 -naphthyl, 2-naphthyl, 3- biphen-1 -yl, anthryl, tetrahydronaphthyl, fluorenyl, indanyl, biphenylenyl, and acenaphthenyl. An aryl group can be unsubstituted or substituted with one or more of the following groups: CrC6alkyl-, halogen, haloalkyl-, hydroxyl, hydroxyl(CrC6alkyl)-, H2N-, amino(C C6alkyl)-, di(CrC6alkyl)amino-, H02C-, (Ci- C6alkoxy)carbonyl-, (C C6alkyl)carboxyl-, di(Ci-C6alkyl)amido-, H2NC(0)-, (C C6alkyl)amido-, or 02N-.
"Di(alkyl)amido-" refers to a -NC(O)- group in which the nitrogen atom of said group is attached to two alkyl groups, as defined above. Each alkyl group can be independently selected. Representative examples of a di(C C6alkyl)amido- group include, but are not limited to, -C(O)N(CH3)2, - C(O)N(CH2CH3)2, -C(O)N(CH3)CH2CH3) -C(0)N(CH2CH2CH2CH3)2, -C(0)N(CH2 CH3)CH2CH2CH3, -C(0)N(CH3)CH(CH3)2l -C(O)N(CH2CH3)CH2CH(CH3)2, - C(0)N(CH(CH3)CH2CH3)2> -C(O)N(CH2CH3)C(CH3)3 and -C(O)N(CH2 CH3)CH2C(CH3)3.
"Di(alkyl)amino-" refers to a nitrogen atom attached to two alkyl groups, as defined above. Each alkyl group can be independently selected. Representative examples of an di(CrC6alkyl)amino- group include, but are not limited to, - N(CH3)2, -N(CH2CH3)(CH3), -N(CH2CH3)2, -N(CH2CH2CH3)2, N(CH2CH2CH2CH3)2, -N(CH(CH3)2)2, -N(CH(CH3)2)(CH3), -N(CH2CH(CH3)2)2, - NH(CH(CH3)CH2CH3)2, -N(C(CH3)3)2, -N(C(CH3)3)(CH3), and -N(CH3)(CH2CH3). The two alkyl groups on the nitrogen atom, when taken together with the nitrogen to which they are attached, can form a 3- to 7- membered nitrogen containing heterocycle wherein up to two of the carbon atoms of the heterocycle can be replaced with -N(H)-, -N(CrC6alkyl)-, -N(C3-C8cycloalkyl)-, -N(C6-C 4aryl)-, -N(d- Cgheteroaryl)-, -N(amino(Ci-C6alkyl))-, -N(C6-Ci4arylamino)-, -O-, -S-, -S(O)-, or - S(0)2-.
"Halo" or "halogen" refers to fluorine, chlorine, bromine, or iodine.
"Haloalkyl-" refers to an alkyl group, as defined above, wherein one or more of the Ci-C6alkyl group's hydrogen atoms has been replaced with -F, -CI, - Br, or -I. Each substitution can be independently selected from -F, -CI, -Br, or -I. Representative examples of an Ci-C6haloalkyl- group include, but are not limited to, -CH2F, -CCI3, -CF3, CH2CF3, -CH2CI, -CH2CH2Br, -CH2CH2I, -CH2CH2CH2F, - CH2CH2CH2CI, -CH2CH2CH2CH2Br, -CH2CH2 CH2CH2 I, -CH CH2CH2CH2CH2Br, - CH2CH2CH2CH2CH2I, -CH2CH(Br)CH3, -CH2CH(CI)CH2CH3, -CH(F)CH2CH3 and - C(CH3)2(CH2CI).
"Heteroaryl-" refers to 5-10-membered mono and bicyclic aromatic groups containing at least one heteroatom selected from oxygen, sulfur, and nitrogen. Examples of monocyclic Ci -Cgheteroaryl- radicals include, but are not limited to, oxazinyl, thiazinyl, diazinyl, triazinyl, thiadiazoyi, tetrazinyl, imidazolyl, tetrazolyl, isoxazolyl, furanyl, furazanyl, oxazolyl, thiazolyl, thiophenyl, pyrazolyl, triazolyl, pyrimidinyl, N-pyridyl, 2-pyridyl, 3-pyridyl, and 4-pyridyl. Examples of bicyclic C Cgheteroaryl- radicals include but are not limited to, benzimidazolyl, indolyl, isoquinolinyl, benzofuranyl, benzothiophenyl, indazolyl, quinolinyl, quinazolinyl, purinyl, benzisoxazolyl, benzoxazolyl, benzthiazolyl, benzodiazolyl, benzotriazolyl, isoindolyl, and indazolyl. The contemplated heteroaryl- rings or ring systems have a minimum of 5 members. Therefore, for example, Ci heteroaryl- radicals would include but are not limited to tetrazolyl, C2heteroaryl- radicals include but are not limited to triazolyl, thiadiazoyi, and tetrazinyl, Cgheteroaryl- radicals include but are not limited to quinolinyl and isoquinolinyl. A heteroaryl group can be unsubstituted or substituted with one or more of the following groups: C-i-C6alkyl-, halogen, CrC6haloalkyl-, hydroxyl, Ci-C6hydroxylalkyl-, H2N-, amino(Ci-C6alkyl), di(Ci-C6alkyl)amino-, -COOH, (CrC6alkoxy)carbonyl-, (CrC6alkyl)carboxyl-, di(CrC6alkyl)ainnido-, H2NC(0)-, (Ci-C6alkyl)amido-, or 02N-.
"Hydroxylalkyl-" refers to an alkyl group, as defined above, wherein one or more of the C-i-Cealkyl group's hydrogen atoms have been replaced with hydroxyl groups. Examples of hydroxyl (C Cealkyl)- moieties include, for example, - CH2OH, -CH2CH2OH, -CH2CH2CH2OH, -CH2CH(OH)CH2OH, -CH2CH(OH)CH3, - CH(CH3)CH2OH and higher homologs.
"Leaving group" refers to an atom or group (charged or uncharged) that becomes detached from an atom in what is considered to be the residual or main part of the substrate in a specified reaction. For example, in the heterolytic solvolysis of benzyl bromide in acetic acid: the leaving group is bromide. In the reaction of N,N,N-trimethyl-1 -phenylmethanaminium ion with methanethiolate, the leaving group is trimethylamine. In the electrophilic nitration of benzene, it is H+. The term has meaning only in relation to a specified reaction. Examples of leaving groups include, for example, carboxylates {i.e. CH3COO~, CF3C02 ", or (CH3)2CH2COO~), F~ water, CI", ΒΓ, Γ, N3 ~ SCNT, trichloroacetimidate, thiopyridyl, tertiary amines (i.e. trimethylamine), phenoxides (i.e. o- nitrophenoxide), and sulfonates (/'. e. tosylate, mesylate, or triflate).
Certain specific aspects and embodiments of the present application will be explained in greater detail with reference to the following examples, which are provided only for purposes of illustration and should not be construed as limiting the scope of the application in any manner. Reasonable variations of the described procedures are intended to be within the scope of the present invention. While particular aspects of the present invention have been illustrated and described, it would be obvious to those skilled in the art that various other changes and modifications can be made without departing from the spirit and scope of the invention. It is therefore intended to cover in the appended claims all such changes and modifications that are within the scope of this invention. EXAMPLES
iylphospholane-CH2O moiety:
Figure imgf000016_0001
air stable ajr stable crystalline solid crystalline solid
Bisphosphite moiety:
Figure imgf000016_0002
1: R= H. Biphenyl
2a:R=H. ( -Binaphthyl
2b:R=H. (S Binaphthyl
3a: R= tBu. (i?)-BIPHEN
3b: R= ¾u. (S)-BIPHEN
Ligand formation:
ive
Figure imgf000016_0003
than chloridite Preparation of ligand (3b)
Figure imgf000017_0001
To a Schlenk flask containing (S)-3,3'-di-teri-butyl-5,5',6,6'-tetramethyl-[1 ,Γ- biphenyl]-2,2'-diol] ((S)-BIPHEN) (2.00 g, 5.64 mmol) and triethylamine (1.65 mL, 1.20 g, 11.84 mmol, 2.1 eq.) was added phosphorus trichloride (517 μί, 814 mg, 5.92 mmol, 1.05 eq.) and the reaction stirred at room temperature overnight. The crude reaction mixture was then filtered under nitrogen atmosphere, toluene (3 x 5 mL portions) added to the residue, and removed under reduced pressure, to remove any residual phosphorus trichloride leaving a colorless solid. The crude 31P NMR (121.4 MHz, C6D6) spectrum showed a single peak at δΡ = 178.8 ppm, corresponding to (S)-BIPHEN chlorophosphite. In a glove box under a nitrogen atmosphere (S)-BIPHEN chlorophosphite (1.0 g, 2.39 mmol) from above was dissolved in toluene, excess trimethylsilyl iodide (1.5 mL, 2.11 g, 10.53 mmol) added and the reaction mixture allowed to stir for 2 hours at room temperature. The excess trimethylsilyl iodide was then removed under reduced pressure and toluene (3 x 5 mL portions) added to the residue and removed under reduced pressure, to remove any residual trimethylsilyl iodide. The crude 31P NMR (121.4 MHz, C6D6) spectrum showed two peaks, one at δρ = 178.8 ppm and another at δΡ = 222.1 ppm indicating only partial conversion to the desired iodo-phosphite (3). This mixture was used in the coupling step below to form ligand (3b), without further purification. Step 2:
Figure imgf000018_0001
All procedures reactions were carried out in a glove box under a nitrogen atmosphere. To a Schlenk flask containing a solution of phospholane (707 mg, 2.39 mmol, 1 eq.) and a mixture of chloro- and iodo-phosphite (2.39 mmol) in toluene (10 ml_), was added 1 ,4-diazabicyclo-[2,2,2]-octane (DABCO, 1 .34 g, 1 1 .95 mmol, 5 eq.) and the solution allowed to stir at room temperature overnight. The product was isolated after filtration through silica as a pale yellow oil, which solidified to pale yellow crystals on standing. Yield: 547 mg, 0.84 mmol, (35%). etc25 = +387.1 ° (c = 0.41 , toluene); 31P NMR (121 .4 MHz, C6D6) δΡ = 139.3 (P1 ), 22.5 (P4); 1H NMR (400 MHz, C6D6) δΗ = 7.00-7.30 (m, 12H, ArCH), 4.09-4.21 (m, 1 H, C3H), 3.24-3.49 (m, 3H, C3H', C5H and C8H), 2.12-2.26 (m, 1 H, C6H or C7H), 2.09 (s, 3H, CH3), 2.08 (s, 3H, CH3), 1.83-1 .95 (m, 2H, C6H2 or C7H2), 1 .78 (s, 3H, CH3), .62 (s, 3H, CH3), 1 .50-1 .60 (m, H, C6H or C7H), 1 .50 (s, 9H, C(CH3)3), 1 .38 (s, 9H, C(CH3)3); 13C NMR (75.5 MHz, C6D6) 6C = 146.73, 146.68, 146.05, 146.03, 144.59, 44.40, 138.52, 138.50, 138.48, 138.45, 137.30, 135.32, 134.59, 132.66, 132.24, 132.19, 131 .62, 131 .27, 131 .24 (ArCquat.), 128.71 , 128.69, 128.62, 128.34, 128.25, 128.00, 127.96, 126.14, 126.12, 126.04, 126.02 (ArCH), 62.40 (dd, 1 JC-P = 29.0, 3.7 Hz, C3), 46.20 (d, 1 JC-P = 15.9 Hz, C5 or C8), 45.45 (d, 1 -P = 14.9 Hz, C5 or C8), 36.42 (C6 or C7), 32.67 (d, 2JC-P = 3.1 Hz, C6 or C7), 31 .76 (d, J = 5.0 Hz, C(CH3)3), 31 .29 (C(CH3)3), 20.4 (CH3), 20.37 (CH3), 16.74 (CH3), 16.45 (CH3).
EXAMPLE 2 Regioselective and enantioselective hydroformylation of allyl benzene.. [Rh(acac)(CO)2] (1 mg, 0.004 mmol, 0.4 mol%) was added into a vial, a stirring bar was added and the vial was sealed with a crimp cap a put under inert atmosphere (N2). Two needles were pierced into the vial and this was introduced into the autoclave. The autoclave was then purged with three vacuum/N2 cycles. A solution of the ligand (Ligand 3a, 3.3 mg, 0.005 mmol, 0.5 mol%) in toluene (1 mL) from a stock solution was added using a syringe. The autoclave was then purged three times with syngas (50/50, CO/H2), pressurized to 5 bar, immersed into an oil bath preheated at 50 °C and stirred at 900 r.p.m for 40 minutes. After this time, the autoclave was cooled down to room temperature by partial immersion in cold water and the pressure released. A solution of alkene (allylbenzene, 118 mg, 133 μΙ, 1 mmol) and internal standard (tetraethylsilane, 30 μΙ) in toluene (1 mL) was added using a syringe. The autoclave was then pressurized back to the desired pressure (5 bar) and stirred at room temperature at 900 r.p.m. After the desired reaction time, (75 hours), the pressure was slowly released and the autoclave was opened. A small sample was taken and analyzed by 1H NMR (CDCI3) to calculate conversion (64%) and branched to linear ratio of the resulting aldehydes (4.00: 1). To determine enantioselectivity (e.e, = 90% for the branched aldehyde), the products were converted into the corresponding alcohols by NaBH4 reduction with the alcohol produce being obtained after work up (dichloromethane (5 mL), quenched with HCI aqueous (5 mL, 1 M), followed by 3 further extractions with dichloromethane (3x10 mL). The combined organic layers were dried over anhydrous MgS0 and the solvent was removed with a rotary evaporator to give the crude mixture which was purified by chromatography on using hexane/EtOAc 4:1 as eluent to give the branched and linear alcohols as a colorless oil (79 mg, 53%). [a]D rt = -12.2 (c 0.5, CHCI3) (for the branched alcohol).
NMR data for branched and linear alcohols.
Figure imgf000019_0001
2-methyl-3-phenylpropan-1-ol: 1H NMR (300 MHz, CDCI3): 6= 0.90 (3H, d, J = 6.8 Hz), 1.43 (1 H, br s), 1.87-1.99 (1 H, m), 2.41 (1 H, dd, J = 13.4, 8.1 Hz), 2.74 (1 H, dd, J = 13.4, 6.3 Hz), 3.46 (1 H, dd, J = 10.6, 6.0 Hz), 3.52 (1 H, dd, J = 10.6, 5.9 Hz), 7.14-7.28 (5H, m); MS (ES+): 173.1 ([MNa]+, 100%). 4-phenylbutan-1-ol:1H NMR (300 MHz, CDCI3): δ= 1.38 (1 H, br s), 1.55- 1.72 (4H, m), 2.62 (2H, t, J = 7.5 Hz), 3.64 (2H, t, J = 6.4 Hz), 7.15-7.28 (5H, m); MS (ES+): 173.1 ([MNa]+, 100%). The enantiomeric excess of the branched alcohol was determined by HPLC on a Chiralcel™ OD-H column, 250 x 4.6 mm, 95:5 n-hexane: 2-propanol, 0.5 ml/min, 210 nm, fR[(-)-(S), major] = 18.6 min, fo[(+)-(ft). minor] = 22.8 min, iR[linear] = 30.2 min.
EXAMPLE 3 Regioselective and enantioselective hydroformylation of hex-1-ene. [Rh(acac)(CO)2] (1 mg, 0.004 mmol, 0.4 mol%) was added into a vial, a stirring bar was added and the vial was sealed with a crimp cap and put under an inert atmosphere (N2). Two needles were pierced into the vial and this was introduced into the autoclave. The autoclave was then purged with three vacuum/N2 cycles. A solution of the ligand (Ligand 3a, 3.3 mg, 0.005 mmol, 0.5 mol%) in toluene (1 ml) from a stock solution was added using a syringe. The autoclave was then purged three times with syngas (50/50, CO/H2), pressurized to 5 bar, immersed into an oil bath preheated at 50 °C and stirred at 900 r.p.m for 40 min. After this time, the autoclave was cooled down to room temperature by partial immersion in cold water and the pressure released. A solution of alkene (1 - hexene, 84 mg, 124 μΙ, 1 mmol) and internal standard (tetraethylsilane, 30 μΙ) in toluene (1 ml) was added using a syringe. The autoclave was then pressurized back to the desired pressure (5 bar) and stirred at room temperature at 900 r.p.m. After the desired reaction time (46 h), the pressure was slowly realized and the autoclave was opened. A small sample was taken and analyzed by 1H NMR (CDCI3) to calculate conversion (70%) and branched to linear ratio of the resulting aldehydes (2.98: 1 ). To determine enantioselectivity (e. e. = 93% for the branched aldehyde), the products were converted into the Cbz-esters of the corresponding alcohols by reduction using NaBH4 and protection in the standard way. NMR data for branched and linear alcohols. [a]D 20 -1 1.6 (c 1.4, CHCI3, e. e. 93%)
Figure imgf000020_0001
2-methylhexan-1-ol: 1H NMR (300 MHz, CDCI3): δ= 0.89 (3H, t, J = 6.9 Hz), 0.91 (3H, d, J = 6.7 Hz), 1.05-1.67 (8H, m), 3.40 (1 H, dd, J = 10.5, 6.5 Hz), 3.50 (1 H, dd, J = 10.5, 5.8 Hz); MS (ES+): 139.1 ([MNa]+, 100%). heptan-1-ol: H NMR (300 MHz, CDCI3): δ= 0.88 (3H, t, J = 6.4 Hz), 1.28- 1 .60 (1 1 H, m), 3.63 (2H, t, J = 6.6 Hz); MS (ES+): 139.1 ([MNa]+, 100%). The enantiomeric excess of the branched Cbz-derived alcohol was determined by HPLC on a tandem of Chiralpak™ AD-H, 250 x 4.6 mm, and Chiralcel™ OD-H, 250 x 4.6 mm, 99:1 n-hexane: 2-propanol, 0.5 ml/min, 210 nm, fR[(-)-(S), major] = 20.5 min, fR[(+)-(fl). minor] = 25.2 min, fR[linear] = 24.2 min.
EXAMPLE 4 Regioselective and enantioselective hydroformylation of pentafluoro-allyl benzene. Using a similar procedure as described in examples 2 and 3, but using pentafluoro-allylbenzene as substrate and a reaction temperature of 40 °C the branched aldehyde was again formed. After the desired reaction time (4 h), the pressure was slowly released and the autoclave was opened. A small sample was taken and analyzed by H NMR (CDCI3) to calculate conversion (90%) and branched to linear ratio of the resulting aldehydes (5.3: 1 ). To determine enantioselectivity (e. e.= 88% for the branched aldehyde), the aldehyde was reduced using NaBH4 in the standard way, with standard purification by chromatography on silica gel using hexane/EtOAc 4:1 as eluent to give the branched and linear alcohols as colorless oil (150 mg, 63%). [a]D 20 = - 8.7 (c 2.75, CHCI3, e. e. 88%);
Figure imgf000021_0001
(-)-2-methyl-3-(perfluorophenyl)propan-1 -ol. 1H NMR (400 MHz, CDCI3): δΗ = 0.92 (d, J = 6.8 Hz, 3H), 1 .77 (s, 1 H), 1 .89-2.01 (m, 1 H), 2.55 (ddt, J = 13.6, 8.4, 1 .7 Hz, 1 H), 2.85 (ddt, J = 13.6, 5.8, 1 .7 Hz, 1 H), 3.50 (dd, J = 8.9, 4.2 Hz, 1 H), 3.54 (dd, J = 8.9, 4.0 Hz, 1 H); 19F NMR (376 MHz, CDCI3): 5F = -163.6- -163.4 (m, 2F), -158.2 (t, J = 20.8 Hz, 1 F), -143.7—143.6 (m, 2F); 13C NMR (75 MHz, CDCI3): 5c = 16.0, 25.9, 36.2, 67.3, 1 13.7-1 14.0 (m), 136.1 -146.4 8 (m); MS (Cl+): 239.0 ([M-2H+H]+, 100%), 240 ([MH]+, 13), 250.0 ([M+NH4]+, 8); HRMS (CI+): m/z = 258.0914 [M+NH4]+, Ci0H13ONF5 requires 258.0912.
4-(perfluorophenyl)butan-1 -ol. H NMR (400 MHz, CDCI3): δΗ = 1 .46 (br s, 1 H), 1 .57-1 .72 (m, 4H), 2.72-2.75 (m, 2H), 3.67 (t, J = 6.2 Hz, 2H); 19F NMR (376 MHz, CDCIs): δΡ = -163.5- -163.4 (m, 2F), -158.5 (t, J = 20.9 Hz, 1 F), - 144.9- -144.8 (m, 2F); 13C NMR (100 MHz, CDCI3): 5C = 22.0, 25.5, 32.0, 62.3, 1 14.7-1 15.0 (m), 136.1 -146.3 (m). The enantiomeric excess of the branched alcohol was determined by HPLC on a tandem series of Chiralpak™ AS-H, 250 x 4.6 mm, and Chiralpak AD-H columns, 250 x 4.6 mm, 99:1 n-hexane: 2-propanol, 0.5 mL/min, 210 nm, fR[(-), major] = 69.1 minutes, fo[(+), minor] = 74.0 minutes, fF near] = 97.2 minutes.
EXAMPLE 5 Regioselective and enantioselective hydroformylation of W-methyl-W-phenylbut-3-enamide. Using a similar procedure as described in examples 2 and 3, but using A/-methyl-/V-phenylbut-3-enamide as substrate and a reaction temperature of 15 °C, the branched aldehyde was again formed. After the desired reaction time (29 h), the pressure was slowly released and the autoclave was opened. A small sample was taken and analyzed by 1H NMR (CDCI3) to calculate conversion (71 %) and branched to linear ratio of the resulting aldehydes (4.5:1 ). To determine enantioselectivity (e. e.= 92% for the branched aldehyde), the aldehyde was reduced using NaBH4 in the standard way, with standard purification by chromatography on SiO2 using EtOAc as eluent to give the branched and linear alcohols as a colorless oil (1 13 mg, 55%). [a]D 20 -7.7 (c 0.85,
Figure imgf000022_0001
(-)-4-hydroxy- V,3-dimethyl-A/-phenylbutanamide. Purified by chromatography on silica gel using EtOAc as eluent to give the branched and linear alcohols as a colorless oil (1 13 mg, 55%). [α]ο20 -7.7 (c 0.85, CHCI3, e. e. 92%); 1H NMR (300 MHz, CDCI3): δ = 0.79 (d, J = 6.3 Hz, 3H), 2.00-2.21 (m, 3H), 3.24 (s, 3H), 3.29-3.34 (m, 2H), 3.50 (dd, J = 10.3, 3.4 Hz, 1 H), 7.14-7.18 (m, 2H), 7.30-7.43 (m, 3H); 13C NMR (75 MHz, CDCI3): δ = 17.2, 33.1 , 37.4, 38.9, 68.1 , 127.2, 127.8, 129.8, 143.9, 173.2; MS (ES+): 230.0 ([MNa]+, 100%); HRMS (ES+): m/z = 230.1 161 [MNa]\ Ci2H17NO2Na requires 230.1 157.
5-hydroxy-A/-methyl-A -phenylpentanamide. H NMR (300 MHz, CDCI3): δΗ = 1 .42-1 .51 (m, 2H), 1 .61 -1 .70 (m, 2H), 2.09 (t, J = 7.0 Hz, 2H), 2.24 (br s, 1 H), 3.25 (s, 3H), 3.54 (t, J = 6.3 Hz, 2H), 7.15-7.18 (m, 2H), 7.31 -7.44 (m, 3H); 13C NMR (75 MHz, CDCI3): 5C = 21 .2, 32.2, 33.6, 37.4, 62.0, 127.3, 127.9, 129.8, 144.1 , 173.3; MS (ES+): 230.0 ([MNa]+, 100%). The enantiomeric excess of the branched alcohol was determined by HPLC on a Chiralpak™ AD-H column, 250 x 4.6 mm, 93:7 n-hexane: 2-propanol, 0.5 mL/min, 254 nm, fo[(-), major] = 33.8 minutes, fFt[(+), minor] = 36.2 minutes, ^[linear] = 41 .2 minutes.
EXAMPLE 6: Regioselective and enantioselective hydroformylation of Vinyl acetate. This reaction was run in an Argonaut Endeavour parallel autoclave system (AE). The vessels of the AE were flushed with Syngas. Stock solutions of [Rh(acac)(CO)2] and ligand 3a were prepared as 1 mg per ml_ solution in toluene. 1 ml of the rhodium stock solution, (1 mg, 0.004 mmol, 0.4 mol%) and a stock solution equivalent to 0.005 mmol (0.5%) of ligand 3a were added into a well in the AE. The mixture was pressurized to 5 bar Syngas and heated at 50 °C for 40 minutes. The pressure was then vented and the apparatus cooled to room temperature. The require substrate (vinyl acetate 1 mmol) was then added also as a stock solution in toluene to bring the reaction vessel up to 3.5 ml_ volume. The apparatus was then purged three times with Syngas, placed at 2.5 bar pressure and heated to 60 °C at constant pressure for 4 hours, after which time no further Syngas uptake was used up (>99% conversion). The AE was then cooled and the reaction mixture analyzed by GC in the standard protocol using a beta- Dex 225 chiral column. This along with NMR revealed that the only product present was the branched aldehyde (B / L >99:1 ) and with an e. e.. of 83 %.
EXAMPLE 7: Regioselective and enantioselective hydroformylation of styrene. This reaction was run in an Argonaut Endeavour parallel autoclave system (AE). The vessels of the AE were flushed with Syngas. Stock solutions of [Rh(acac)(CO)2] and ligand 3a were prepared as 1 mg per mL solution in toluene. 1 ml of the rhodium stock solution, (1 mg, 0.004 mmol, 0.4 mol%) and a stock solution equivalent to 0.005 mmol (0.5%) of ligand 3a were added into a well in the AE. The mixture was pressurized to 5 bar Syngas and heated at 50 °C for 40 minutes. The pressure was then vented and the apparatus cooled to room temperature. The require substrate (styrene 1 mmol) was then added also as a stock solution in toluene to bring the reaction vessel up to 3.5 mL volume. The apparatus was then purged three times with Syngas, placed at 10 bar pressure and heated to 60 °C at constant pressure for 6 hours, after which time no further Syngas uptake was used up (>99% conversion). The AE was then cooled and the reaction mixture analyzed by GC in the standard protocol using a beta-Dex 225 chiral column. This revealed >99% conversion to aldehydes, (B / L = 79.3:1 ) and with an e. e.. of 92 %.
EXAMPLE 8: Regioselective and enantioselective hydroformylation of allyl cyanide. This reaction was run in an Argonaut Endeavour parallel autoclave system (AE). The vessels of the AE were flushed with Syngas. Stock solutions of [Rh(acac)(CO)2] and ligand 3a were prepared as 1 mg per ml_ solution in toluene. 1 ml of the rhodium stock solution, (1 mg, 0.004 mmol, 0.4 mol%) and a stock solution equivalent to 0.005 mmol (0.5%) of ligand 3a were added into a well in the AE. The mixture was pressurized to 5 bar Syngas and heated at 50 °C for 40 minutes. The pressure was then vented and the apparatus cooled to room temperature. The require substrate (allyl cyanide, 1 mmol) was then added also as a stock solution in toluene to bring the reaction vessel up to 3.5 mL volume. The apparatus was then purged three times with Syngas, placed at 10 bar pressure and heated to 30 °C at constant pressure for 14 hours, after which time no further Syngas uptake was used up (>99% conversion). The AE was then cooled and the reaction mixture analyzed by 1H NMR spectroscopy utilizing enantiopure (fl)-1 -phenylpropan-1 -amine as a chiral derivatizing agent to facilitate calculation of enantiomeric excess, with the branched selectivity and conversion also measured using NMR. In some cases conversion, and branched to linear were also checked using chiral CG using an alpha-Dex 225 column. This revealed >99% conversion, a B : L = 10.0:1 and an e. e.. of 81 %.
Throughout this application, various publications are referenced. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art as known to those skilled therein as of the date of the invention described and claimed herein.
While particular embodiments of the present invention have been illustrated and described, it would be obvious to those skilled in the art that various other changes and modifications can be made without departing from the spirit and scope of the invention. It is therefore intended to cover in the appended claims all such changes and modifications that are within the scope of this invention.

Claims

CLAIMS:
1. A compound of the formula 4:
Figure imgf000026_0001
4
wherein n and m are each independently an integer from 1 to 3;
Ar1 are both independently C6-Ci4aryl or Ci -Cgheteroaryl, which can be unsubstituted or substituted with one or more of the following groups: CrC6alkyl-, halogen, Ci-C6haloalkyl-, hydroxyl, hydroxyl(CrC6alkyl)-, H2N-, (C C6alkyl)amino-, di(Ci-C6alkyl)amino-, HO2C-, (Ci-C6alkoxy)carbonyl-, (C C6alkyl)carboxyl-, di(C C6alkyl)amido-, H2NC(0)-, (Ci-C6alkyl)amido-, or 02N-; and
-Ai^-Ar2- is a bi(C6-Ci4aryl), bi(Ci -Cgheteroaryl), or -(C6-Ci4aryl)-(C Cgheteroaryl)- diradical, which can be unsubstituted or substituted with one or more of the following groups: CrC6alkyl-, halogen, d-C6haloalkyl-, hydroxyl, hydroxyl(C C6alkyl)-, H2N-, (C C6alkyl)amino-, di(C C6alkyl)amino-, H02C-, (d- C6alkoxy)carbonyl-, (CrC6alkyl)carboxyl-, di(C C6alkyl)amido-, H2NC(O)-, (Ci- C6alkyl)amido-, or O2N-.
2. The compound of claim 1 , wherein -Ai^-Ar2- is a bi(C6-Ci4aryl) diradical, which can be unsubstituted or substituted with one or more of the following groups: C C6alkyl-, halogen, CrC6haloalkyl-, hydroxyl, hydroxyl(CrC6alkyl)-, H2N-, (C C6alkyl)amino-, di(Ci-C6alkyl)amino-, H02C-, (CrC6alkoxy)carbonyl-, (C C6alkyl)carboxyl-, di(CrC6alkyl)amido-, H2NC(0)-, (CrC6alkyl)amido-, or 02N-.
3. The compound of claim 2, wherein -Ai^-Ar2- is a biphenyl diradical, which can be unsubstituted or substituted with one or more of the following groups: C C6alkyl-, halogen, C C6haloalkyl-, hydroxyl, hydroxyl(CrC6alkyl)-, H2N-, (Ci- C6alkyl)amino-, di(CrC6alkyl)amino-, H02C-, (C-i-C6alkoxy)carbonyl-, (C C6alkyl)carboxyl-, di(CrC6alkyl)amidc~, H2NC(0)-, (Ci-C6alkyl)amido-, or 02N-.
4. The compound of claim 3, wherein -At^-Ar2- is a 2,2'-biphenyl diradical, which can be unsubstituted or substituted with one or more of the following groups: CrC6alkyl-, halogen, C-i-C6haloalkyl-, hydroxyl, hydroxyl(CrC6alkyl)-, H2N-, (d- C6alkyl)amino-, di(C C6alkyl)amino-, HO2C-, (CrC6alkoxy)carbonyl-, (C C6alkyl)carboxyl-, di(C C6alkyl)amido-, H2NC(0)-, (CrC6alkyl)amido-, or 02N-.
5. The compound of claim 4, wherein -Ar^-Ar2- is a 2,2'-biphenyl diradical, substituted with one or more CrC6alkyl- groups.
6. The compound of any one of claims 1 to 5, wherein Ar1 are both independently C6-Ci aryl.
7. The compound of any one of claims 1 to 6, wherein Ar1 are both phenyl.
8. The compound of any one of claims 1 to 7, wherein n and m are both 1.
9. The compound of any one of claims 1 to 8, which is of the formulae 1, 2a, 2b, 3a, or 3b:
Figure imgf000027_0001
1 -27-
Figure imgf000028_0001
Figure imgf000028_0002
1 1. A process for the synthesis of the ligands of formula 4 of claim 1 comprising:
Figure imgf000029_0001
4
wherein X is a leaving group.
12. A process for the asymmetric hydroformyiation of prochiral olefins in the presence of Rh catalysts derived from ligands of formula 4, of claim 1.
13. The process of claim 12, wherein the prochiral terminal olefin is RCH2CH=CH2, wherein R is C6-Caryl, d-Cgheteroaryl, or Ci-C-6alkyl, and any C6- Caryl, d-Cgheteroaryl, or CrC6alkyl radical, is optionally substituted by one or more with one or more of the following groups: halogen, H2N-, (CrC6alkyl)amino-, di(Ci-C6alkyl)amino-, (Ci-C6alkyl)C(0)N(Ci-C3alkyl)-, (Ci-C6alkyl)carboxyamido-, HC(0)NH-, H2NC(0)-, (CrC6alkyl)NHC(0)-, di(Ci-C6alkyl)NC(0)-, NC-, hydroxyl, CrC6alkoxy-, Ci-C6alkyl-, H02C-, (C C6alkoxy)carbonyl-, (C C6alkyl)C(O)-, C6- Ci4aryl-, CrCgheteroaryl-, C3-C8cycloalkyl-, CrC6haloalkyl-, amino(Ci-C6alkyl)-, (Ci-C6alkyl)carboxyl-, Ci-C6carboxyamidoalkyl-, or 02N-.
14. The process of claim 12, wherein the prochiral olefin is styrene and the hydroformyiation uses Syn gas in the presence of Rh catalysts derived from ligands of formul
Figure imgf000029_0002
15. The process of claim 12, wherein the prochiral olefin is allyl cyanide and the hydroformylation uses Syn gas in the presence of Rh catalysts derived from ligands of formula 4, the process comprising:
Figure imgf000030_0001
16. The process of claim 12, wherein the prochiral olefin is vinyl acetate and hydroformylation uses Syn gas in the presence of Rh catalysts derived from ligands of formula 4 the process comprising:
Figure imgf000030_0002
17. The process of claim 13, wherein the regioselectivity of the hydroformylation in favor of the linear aldehyde product is reversed towards the branched aldehyde product.
PCT/US2011/045897 2010-07-30 2011-07-29 Ligands for selective asymmetric hydroformylation WO2012016147A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP11813250.5A EP2598510A4 (en) 2010-07-30 2011-07-29 Ligands for selective asymmetric hydroformylation
JP2013522001A JP2013532691A (en) 2010-07-30 2011-07-29 Ligands for selective asymmetric hydroformylation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36923810P 2010-07-30 2010-07-30
US61/369,238 2010-07-30

Publications (2)

Publication Number Publication Date
WO2012016147A2 true WO2012016147A2 (en) 2012-02-02
WO2012016147A3 WO2012016147A3 (en) 2012-04-19

Family

ID=45530741

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/045897 WO2012016147A2 (en) 2010-07-30 2011-07-29 Ligands for selective asymmetric hydroformylation

Country Status (3)

Country Link
EP (1) EP2598510A4 (en)
JP (1) JP2013532691A (en)
WO (1) WO2012016147A2 (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9308527B2 (en) 2014-03-17 2016-04-12 Eastman Chemical Company Phosphorous compounds useful as ligands and compositions and methods regarding them
CN104744514B (en) * 2013-12-27 2018-03-23 中国科学院上海药物研究所 A kind of chiral phosphorus alkene part, synthetic method and its application in asymmetric reaction
WO2019108501A1 (en) * 2017-11-28 2019-06-06 Eastman Chemical Company Highly isoselective catalyst for alkene hydroformylation
US10351583B2 (en) 2017-11-28 2019-07-16 Eastman Chemical Company Highly isoselective catalyst for alkene hydroformylation
WO2022046420A1 (en) * 2020-08-25 2022-03-03 Eastman Chemical Company Phospholane-phosphite ligands for alkene hydroformylation catalysts
WO2022046421A1 (en) * 2020-08-25 2022-03-03 Eastman Chemical Company Olefin hydroformylation processes using hydrocarbon solvents and fluorinated solvents in the presence of phospholane-phosphite ligands
US11542278B1 (en) 2020-05-05 2023-01-03 Nuvalent, Inc. Heteroaromatic macrocyclic ether chemotherapeutic agents
US11667649B2 (en) 2020-05-05 2023-06-06 Nuvalent, Inc. Heteroaromatic macrocyclic ether chemotherapeutic agents
US12043626B2 (en) 2021-10-01 2024-07-23 Nuvalent, Inc. Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3846020B2 (en) * 1998-04-07 2006-11-15 三菱化学株式会社 Bisphosphite compound and method for producing aldehydes using the compound

Non-Patent Citations (16)

* Cited by examiner, † Cited by third party
Title
"Asymmetric hydroformylation catalyzed by an Rh(I)-(R,S)-BINA HOS complex: substituent effects on the regioselectivity", J. ORGANOMET. CHEM., vol. 527, 1997, pages 103
"Asymmetric Hydroformylation of Olefins with Rh Catalysts Modified with Chiral Phosphine-Phosphite Ligands", ORGANOMETALLICS, vol. 26, no. 25, 2007, pages 6428
"Asymmetric Hydroformylation Using Taddol-Based Chiral Phosphine-Phosphite Ligands", ORGANOMETALLICS, vol. 29, no. 2, 2010, pages 478
"Branched Selective Hydroformylation", CURR. ORG. CHEM., vol. 9, 2005, pages 701
"Highly Enantioselective Hydroformylation of Aryl Alkenes with Diazaphospholane Ligands", ORGANIC LETTERS, vol. 10, no. 20, 2008, pages 4553
"Hydrogenation Processes in the Synthesis of Perfumery Ingredients", ACC. CHEM. RES., vol. 40, 2007, pages 1312
"Recent Advances in Chemo-, Regio- and Stereoselective Hydroformylation", SYNTHESIS, 2001, pages 1
"Rhodium(I), Palladium(II), and Patnum( ) Complexes Containing New Mixed Phosphane-Phoshite Ligands - Effect of the Catalytic System stability on the Enantioselective Hydroformylation of Styrene", EUR. J. INORG. CHEM., 2002, pages 711
"Substituent Effect in Asymmetric Hydroformylation of Olefins Catalysed by Rhodium(l) Complexes of (R,S)-BINAPHOS Derivatives: A protocol for improvement of regio- and enantioselectivities", ADV. SYNTH. CATAL., vol. 343, 2001, pages 61
"Synthesis of a chiral phosphite-phosphine ligand, its coordination behavior with rhodium(l) cation and the application in catalytic reaction", ZHONGSHAN DAXUE XUEBAO, ZIRAN KEXUEBAN, vol. 45, no. 4, 2006, pages 58
"The Synthesis of the High Potency Sweetener NC-00637 Part 1: The Synthesis of (S)-2-Methyl Hexanoic Acid", ORG. PROC. RES. DEV., vol. 7, 2003, pages 369
"Tuning of the structures of chiral phosphane-phosphites: application to the highly enantioselective synthesis of a-acyloxy phosphonates by catalytic hydrogenation", CHEMISTRY-A EUROPEAN JOURNAL, vol. 13, no. 6, 2007, pages 1821
KLOSIN ET AL., ANGEW. CHEM. INT. ED., vol. 44, 2005, pages 5834
See also references of EP2598510A4
TAKAYA ET AL., J. AM. CHEM. SOC., vol. 119, 1997, pages 4413
WHITEKER ET AL., J. ORG. CHEM., vol. 6, 2004, pages 3277

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104744514B (en) * 2013-12-27 2018-03-23 中国科学院上海药物研究所 A kind of chiral phosphorus alkene part, synthetic method and its application in asymmetric reaction
US9308527B2 (en) 2014-03-17 2016-04-12 Eastman Chemical Company Phosphorous compounds useful as ligands and compositions and methods regarding them
CN111315755B (en) * 2017-11-28 2024-03-01 伊士曼化工公司 High isomerism selectivity catalyst for hydroformylation of olefins
CN111315755A (en) * 2017-11-28 2020-06-19 伊士曼化工公司 Highly isomerically selective catalysts for the hydroformylation of olefins
CN111315483A (en) * 2017-11-28 2020-06-19 伊士曼化工公司 Highly isomerically selective catalysts for the hydroformylation of olefins
US10351583B2 (en) 2017-11-28 2019-07-16 Eastman Chemical Company Highly isoselective catalyst for alkene hydroformylation
WO2019108501A1 (en) * 2017-11-28 2019-06-06 Eastman Chemical Company Highly isoselective catalyst for alkene hydroformylation
US11667649B2 (en) 2020-05-05 2023-06-06 Nuvalent, Inc. Heteroaromatic macrocyclic ether chemotherapeutic agents
US12275742B2 (en) 2020-05-05 2025-04-15 Nuvalent, Inc. Heteroaromatic macrocyclic ether chemotherapeutic agents
US11542278B1 (en) 2020-05-05 2023-01-03 Nuvalent, Inc. Heteroaromatic macrocyclic ether chemotherapeutic agents
US12054498B2 (en) 2020-05-05 2024-08-06 Nuvalent, Inc. Heteroaromatic macrocyclic ether chemotherapeutic agents
WO2022046420A1 (en) * 2020-08-25 2022-03-03 Eastman Chemical Company Phospholane-phosphite ligands for alkene hydroformylation catalysts
CN115989210A (en) * 2020-08-25 2023-04-18 伊士曼化工公司 Phospholane-phosphite ligands for olefin hydroformylation catalysts
CN115989211A (en) * 2020-08-25 2023-04-18 伊士曼化工公司 Olefin hydroformylation process using hydrocarbon solvent and fluorinated solvent in the presence of phospholane-phosphite ligand
WO2022046421A1 (en) * 2020-08-25 2022-03-03 Eastman Chemical Company Olefin hydroformylation processes using hydrocarbon solvents and fluorinated solvents in the presence of phospholane-phosphite ligands
US12043626B2 (en) 2021-10-01 2024-07-23 Nuvalent, Inc. Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds

Also Published As

Publication number Publication date
EP2598510A4 (en) 2014-02-26
WO2012016147A3 (en) 2012-04-19
JP2013532691A (en) 2013-08-19
EP2598510A2 (en) 2013-06-05

Similar Documents

Publication Publication Date Title
WO2012016147A2 (en) Ligands for selective asymmetric hydroformylation
Nozaki et al. Highly enantioselective hydroformylation of olefins catalyzed by rhodium (I) complexes of new chiral phosphine− phosphite ligands
JP2966094B2 (en) Asymmetric synthesis
Scarso et al. Highly active and selective platinum (II)-catalyzed isomerization of allylbenzenes: Efficient access to (E)-anethole and other fragrances via unusual agostic intermediates
TW591011B (en) Process for the telomerization of acyclic olefins
Alvarez et al. Synthesis and reactivity of indenyl ruthenium (II) complexes containing the labile ligand 1, 5-cyclooctadiene (COD): catalytic activity of [Ru (η5-C9H7) Cl (COD)]
JP6395714B2 (en) Ruthenium-based metathesis catalysts, precursors for their production and their use
JP2014520089A (en) Ligands and catalyst systems for hydroformylation processes
Gu et al. Use of ligand steric properties to control the thermodynamics and kinetics of oxidative addition and reductive elimination with pincer-ligated Rh complexes
Franzke et al. Synthesis of new serine-based phosphinooxazoline ligands and iridium complexes for asymmetric hydrogenations
Lustenberger et al. Towards Asymmetric Catalysis in the Major Groove of 1, 1′‐Binaphthalenes
Masui et al. Synthesis and structures of heterobimetallic Ir2M (M Pd, Pt) sulfido clusters and their catalytic activity for regioselective addition of alcohols to internal 1-aryl-1-alkynes
Farkas et al. Phosphine–phosphite ligands: chelate ring size vs. activity and enantioselectivity relationships in asymmetric hydrogenation
JP5551239B2 (en) Palladium phosphine complexes for butadiene telomerization.
TWI517899B (en) Biaryl diphosphine ligands, intermediates of the same and their use in asymmetric catalysis
Gómez et al. New chiral tetradentate oxazolinylphosphine ligands for nickel and palladium. Coordination behavior and catalytic activity in allylic alkylations
JP2007063275A (en) Allyl alkylation by iron catalysis
Zimmermann et al. Mono‐and Bidentate Phosphine Ligands in the Palladium‐Catalyzed Methyl Acrylate Dimerization
Tuba et al. Synthesis, structure, and reactivity of fluorous phosphorus/carbon/phosphorus pincer ligands and metal complexes
Yasuike et al. Synthesis of JOSIPHOS-type ligands via a diastereoselective three-component reaction and their application in asymmetric rhodium-catalyzed hydroborations
JP4928798B2 (en) Catalyst for asymmetric synthesis, ligand used therein, and method for producing optically active compound by asymmetric synthesis reaction using them
JP2005523939A (en) Ferrocenyl ligand and method for producing the ligand
Spittler Frustrated Lewis Pair-Catalysed Functionalisation of Alkenes with Iodoperfluoroalkanes and Gold-Catalysed Desymmetrisation of 1, 4-Diynes
EP1846350A2 (en) Improved method for the preparation of enantiomerically enriched secondary alcohols by the addition of organoaluminium reagents to carbonyl compounds
CA1086771A (en) Asymmetric catalysis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11813250

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2013522001

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2011813250

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2011813250

Country of ref document: EP